natgillin/translations-raw huggingface dataset:
Contains E110, E216, E218, sodium and propylene glycol, see leaflet for further information. 
SEZNAM POMOŽNIH SNOVI Vsebuje E110, E216, E218, natrij in propilenglikol, za nadaljnje informacije glejte navodilo za uporabo.
These are only suitable for patients who weigh at least 33 kg and can swallow hard capsules. 
Te so primerne samo za bolnike, ki tehtajo najmanj 33 kg in ki lahko pogoltnejo trdo kapsulo.
This active substance is an antiretroviral medicine which is used to treat HIV infection. 
Ta zdravilna učinkovina je protiretrovirusno zdravilo, ki se uporablja za zdravljenje okužbe z virusom HIV.
Intracellular triphosphate levels increased with dose, but reached a plateau at doses of 200 mg or greater. 
Nivo znotrajceličnega trifosfata s količino zdravila narašča, vendar doseže svoj plato pri odmerku 200 mg ali več.
2 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients (see section 4.8, Paediatric population). 
2 Anemija je bila pogosta in sprememba obarvanosti kože (povečana pigmentacija) je bila zelo pogosta pri uporabi emtricitabina pri pediatričnih bolnikih (glejte poglavje 4.8, Pediatrična populacija).
Speak with your doctor before you stop, particularly if you are experiencing any side effects or you have another illness. 
Preden prenehate z zdravljenjem, se pogovorite z zdravnikom, še zlasti če imate kakršnekoli neželene učinke ali kakšno drugo bolezen.
Warnings and precautions • Tell your doctor if you have had kidney disease, or if tests have shown problems with your kidneys. 
• Obvestite svojega zdravnika, če ste kdaj prej imeli bolezni ledvic ali če so preiskave kazale na težave z ledvicami.
Your doctor may also order blood tests during treatment to monitor your kidneys. 
Vaš zdravnik bo morda naredil krvne preiskave v času zdravljenja, da bo nadzoroval stanje vaših ledvic.
For infants from 4 months, children, and patients who are unable to swallow hard capsules and patients with kidney problems, Emtriva is available as a liquid (an oral solution). 
Za dojenčke, stare najmanj 4 mesece, otroke in bolnike, ki ne morejo pogoltniti trde kapsule, in za bolnike z ledvičnimi težavami je zdravilo Emtriva na voljo tudi kot tekočina (peroralna raztopina).
Emtriva 200 mg hard capsules are available for adults, adolescents and children who weigh at least 33 kg and can swallow hard capsules. 
Emtriva 200 mg trde kapsule so na voljo odraslim, mladostnikom in otrokom, katerih teža je najmanj 33 kg in lahko pogoltnejo trdo kapsulo.
Emtriva oral solution is particularly suitable for people who have difficulty in swallowing Emtriva hard capsules. 
Peroralna raztopina Emtriva je še zlasti primerna za bolnike, ki imajo težave s požiranjem trdih kapsul Emtriva.
If you forget to take Emtriva 
Če ste pozabili vzeti zdravilo Emtriva
Emtricitabine did not exhibit cytotoxicity to peripheral blood mononuclear cells (PBMCs), established lymphocyte and monocyte-macrophage cell lines or bone marrow progenitor cells in vitro. 
Emtricitabin ni izkazal citotoksičnosti za periferne mononuklearne krvne celice (PBMC, peripheral blood mononuclear cells), etablirane limfocite, monocitne-makrofagne celične linije ali matične celice kostnega mozga pri in vitro pogojih.
Pharmacokinetic parameters were determined following administration of a single dose of 200 mg emtricitabine hard capsules to 30 non-HIV infected subjects with varying degrees of renal insufficiency. 
Farmakokinetični parametri so bili določeni po uporabi enega odmerka 200 mg emtricitabina v obliki trdih kapsul pri 30 osebah, ki niso bile okužene z virusom HIV in so imele različne stopnje ledvične insuficience.
Patients with renal impairment: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency. 
Bolniki z motnjami v delovanju ledvic: Emtricitabin se izloča preko ledvic in izpostavljenost emtricitabinu je pomembno narasla pri bolnikih z ledvično insuficienco.
Age Pharmacokinetic data are not available in the elderly (over 65 years of age). 
Farmakokinetični podatki zdravila pri starostnikih (starih nad 65 let), niso na razpolago.
What you need to know before you take Emtriva Do not take Emtriva 
Kaj morate vedeti, preden boste vzeli zdravilo Emtriva Ne jemljite zdravila Emtriva
With the exception of famciclovir and tenofovir disoproxil fumarate, the effect of co-administration of emtricitabine with medicinal products that are excreted by the renal route, or other medicinal products known to affect renal function, has not been evaluated. 
Z izjemo famciklovira in dizoproksiltenofovirata fumarata niso bili ovrednoteni učinki sočasne uporabe emtricitabina z zdravili, ki se izločajo po ledvični poti, ali z drugimi zdravili, za katera je znano, da vplivajo na ledvično funkcijo.
In a pilot study in children and a definitive bioequivalence study in adults, the Emtriva 10 mg/mL oral solution was shown to have approximately 80% of the bioavailability of the Emtriva 200 mg hard capsules. 
V pilotski študiji pri otrocih in bioekvivalentni študiji pri odraslih je biološka uporabnost Emtriva 10 mg/ml peroralne raztopine predstavljala približno 80 % biološke uporabnosti Emtriva 200 mg trdih kapsul.
Do not give Emtriva to infants under 4 months of age. 
Zdravila Emtriva ne dajajte dojenčkom, starim manj kot 4 mesece.
This medicine also contains 480 mg propylene glycol per 24 mL (maximum single dose) which is equivalent to a maximum of 12 mg/kg/day. 
To zdravilo vsebuje tudi 480 mg propilenglikola na 24 ml (največji enkratni odmerek), kar ustreza največ 12 mg/kg/dan.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART. 
Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo CART ali obojim.
The recommended dose is: • Adults: one 200 mg hard capsule, each day with or without food. 
Priporočeni odmerek je: • Odrasli: ena 200 mg trda kapsula dnevno z ali brez hrane.
There is no experience of the use of emtricitabine in patients who are failing their current regimen or who have failed multiple regimens. 
Ni izkušenj z uporabo emtricitabina pri bolnikih, ki niso uspeli s dotedanjim režimom zdravljenja ali niso uspeli z različnimi režimi zdravljenja.
Antiviral activity in vitro: The 50% inhibitory concentration (IC50) value for emtricitabine against laboratory and clinical isolates of HIV-1 was in the range of 0.0013 to 0.5 µmol/l. 
Antivirusno učinkovanje in vitro: 50 % inhibitorna koncentracija (IC50) vrednost emtricitabina proti laboratorijskim in kliničnim izolatom virusa HIV-1 je bila v razponu od 0,0013 do 0,5 µmol/l.
Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ. 
Emtricitabin je šibek zaviralec sesalske DNA-polimeraze α, β in ε ter mitohondrijske DNA-polimeraze γ.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/mL. 
In vitro je bila vezava emtricitabina na humane plazemske proteine manj kot 4 % in je neodvisna od koncentracije v razponu med 0,02 in 200 µg/ml.
Emtriva 200 mg hard capsules are only suitable for patients who weigh at least 33 kg. Emtriva oral solution is available for people who have difficulty in swallowing Emtriva hard capsules. 
Emtriva 200 mg trde kapsule so primerne le za bolnike, ki tehtajo najmanj 33 kg. Peroralna raztopina Emtriva je na voljo za bolnike, ki imajo težave s požiranjem trdih kapsul Emtriva.
Each blister pack contains 30 hard capsules. 
Vsak pretisni omot vsebuje 30 trdih kapsul.
Skin discolouration (increased pigmentation): Skin discolouration, manifested by hyperpigmentation mainly on the palms and/or soles, was generally mild, asymptomatic and of little clinical significance. 
Sprememba obarvanosti kože (povečana pigmentacija): Sprememba obarvanosti kože, ki se kaže kot hiperpigmentacija zlasti na dlaneh in/ali podplatih, je bila povečini blage oblike, asimptomatična in klinično le malo pomembna.
Emtriva is also available as hard capsules. 
Zdravilo Emtriva je na razpolago tudi v obliki trdih kapsul.
Emtricitabine exposure may be markedly increased in patients with severe renal insufficiency (creatinine clearance < 30 mL/min) receiving daily doses of 200 mg emtricitabine as hard capsules or 240 mg as the oral solution. 
Izpostavljenost emtricitabinu se lahko pomembno poveča pri bolnikih z resno ledvično insuficienco (očistek kreatinina < 30 ml/min), ki prejemajo dnevni odmerek 200 mg emtricitabina v obliki trdih kapsul ali 240 mg v obliki peroralne raztopine.
There is no clinical experience as yet on the co-administration of cytidine analogues. 
Ni kliničnih izkušenj o sočasni uporabi analogov citidina.
The absolute bioavailability of emtricitabine from Emtriva 200 mg hard capsules was estimated to be 93% and the absolute bioavailability from Emtriva 10 mg/mL oral solution was estimated to be 75%. 
Ocenjena absolutna biološka uporabnost emtricitabina, uporabljenega v obliki Emtriva 200 mg trde kapsule, je 93 % in ocenjena absolutna vrednost biološke uporabnosti emtricitabina, uporabljenega v obliki Emtriva 10 mg/ml peroralne raztopine, je 75 %.
Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. 
Celični encimi fosforilirajo emtricitabin v emtricitabin 5'-trifosfat, ki kompetitivno inhibira HIV-1 reverzno transkriptazo, kar rezultira v prekinitvi verige DNA.
Each dose (24 mL) contains 36 mg methyl parahydroxybenzoate (E218), 3.6 mg propyl parahydroxybenzoate (E216), 1.2 mg sunset yellow (E110), 480 mg propylene glycol and has a sodium content of 36 mg. 
Vsak odmerek (24 ml) vsebuje 36 mg metilparahidroksibenzoata (E218), 3,6 mg propilparahidroksibenzoata (E216), 1,2 mg oranžnega FCF (E110), 480 mg propilenglikola in 36 mg natrija.
The safety and efficacy of the reduced doses provided in section 4.2 are based on single dose pharmacokinetic data and modelling and have not been clinically evaluated. 
Varnost in učinkovitost zmanjšanega odmerka, kot je prikazano v poglavju 4.2, temeljita na farmakokinetičnih podatkih pri enkratnem odmerku in modeliranju ter še nista bili klinično ovrednoteni.
If you take more Emtriva than you should 
Če ste vzeli večji odmerek zdravila Emtriva, kot bi smeli
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) which works by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the HIV virus to reproduce itself. 
Emtricitabin je nukleozidni zaviralec reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitor), ki deluje tako, da vpliva na normalno delovanje encima (reverzne transkriptaze), ki je bistven za reproduciranje virusa HIV.
Emtriva should not be taken with any other medicinal products containing emtricitabine or medicinal products containing lamivudine. 
Zdravila Emtriva se ne sme jemati z nobenimi drugimi zdravili, ki vsebujejo emtricitabin ali zdravili,
Children given emtricitabine also experienced changes in skin colour including darkening of the skin in patches, very commonly and anaemia (low red blood cell count), commonly. 
Pri otrocih, ki so prejemali emtricitabin, je bila zelo pogosta tudi sprememba obarvanosti kože, vključujoč temne lise in pogosta anemija (nizko število rdečih krvnih telesc).
Liver function 
Ledvična funkcija
The safety and efficacy of the dose interval adjustment guidelines provided in section 4.2 are based on single dose pharmacokinetic data and modelling and have not been clinically evaluated. 
Varnost in učinkovitost smernic prilagoditve intervala odmerjanja, ki so predstavljene v poglavju 4.2, temeljita na farmakokinetičnih podatkih pri enkratnem odmerku in modeliranju ter še nista bili klinično ovrednoteni.
At 48 weeks of treatment the emtricitabine-containing regimen demonstrated an equivalent proportion of patients with HIV RNA < 400 copies/mL (94% emtricitabine versus 92%) and a greater proportion of patients with HIV RNA < 50 copies/mL (95% emtricitabine versus 87%) compared with the patients continuing with their PI-HAART regimen. 
V času 48-tedenskega režima zdravljenja, ki je vsebovalo emtricitabin, se je izkazal ekvivalentni delež bolnikov s HIV RNA < 400 virionov/ml (94 % z emtricitabinom proti 92 %) in večji delež bolnikov s HIV RNA < 50 virionov/ml (95 % emtricitabina proti 87 %) v primerjavi z bolniki, ki so nadaljevali s svojim PI-HAART režimom.
Before starting treatment, your doctor may order blood tests to assess kidney function and may advise you to take the capsules less often or prescribe Emtriva oral solution. 
Pred začetkom zdravljenja bo zdravnik morda naredil krvne preiskave, da bo ocenil delovanje ledvic in vam morda svetoval, da jemljete kapsule manj pogosto ali vam bo predpisal peroralno raztopino Emtriva.
Assessment of adverse reactions in paediatric patients from clinical study data is based on experience in three paediatric studies (n = 169) where treatment-naïve (n = 123) and treatment-experienced (n = 46) paediatric HIV infected patients aged 4 months to 18 years were treated with emtricitabine in combination with other antiretroviral agents. 
Ugotavljanje neželenih reakcij pri pediatričnih bolnikih iz podatkov kliničnih študij temelji na izkušnjah treh pediatričnih študij (n = 169), v katerih so bili pediatrični bolniki, okuženi z virusom HIV, ki se zdravijo prvič (n = 123), in bolniki pediatrični, okuženi z virusom HIV, ki se zdravijo že dalj časa (n = 46), v starosti od 4 mesecev do 18 let, zdravljeni z emtricitabinom v kombinaciji z drugo protiretrovirusno učinkovino.
HIV/HBV co-infected patients: The adverse reaction profile in patients co-infected with HBV is similar to that observed in patients infected with HIV without co-infection with HBV. 
Bolniki s hkratno okužbo HIV/HBV: Neželene reakcije pri bolnikih, ki so hkrati okuženi še s HBV, so podobne tistim, ki jih imajo bolniki, okuženi z virusom HIV brez hkratne okužbe s HBV.
If a patient misses a dose of Emtriva by more than 12 hours and it is almost time for their next dose, the patient should not take the missed dose and simply resume the usual dosing schedule. 
Če bolnik izpusti odmerek zdravila Emtriva za več kot 12 ur in je že skoraj čas za naslednji odmerek, naj bolnik ne nadomesti izpuščenega odmerka in preprosto nadaljuje z jemanjem po običajnem režimu odmerjanja.
Emtricitabine is primarily excreted via glomerular filtration and active tubular secretion. 
Emtricitabin se primarno izloča preko glomerularne filtracije in aktivne tubularne sekrecije.
Paediatric population: The recommended dose of Emtriva for children aged 4 months and over and adolescents up to 18 years of age weighing at least 33 kg who are able to swallow hard capsules is one 200 mg hard capsule, taken orally, once daily. 
Pediatrična populacija: Priporočeni odmerek zdravila Emtriva za otroke, stare 4 mesece ali več in mladostnike, stare do 18 let, s telesno težo najmanj 33 kg, ki lahko pogoltnejo trdo kapsulo, je ena 200 mg trda kapsula, peroralno, enkrat dnevno.
In addition to the adverse reactions reported in adults (see section 4.8, Tabulated summary of adverse reactions), the following adverse reactions were observed more frequently in paediatric patients: anaemia was common (9.5%) and skin discolouration (increased pigmentation) was very common (31.8%) in paediatric patients. 
Poleg neželenih reakcij, o katerih so poročali pri odraslih (glejte poglavje 4.8, Povzetek neželenih reakcij, prikazan v preglednici), so pri pediatričnih bolnikih pogosteje opazili naslednje neželene reakcije: anemija je bila pogosta (9,5 %) in sprememba obarvanosti kože (zvečana pigmentacija) je bila zelo pogosta (31,8 %) pri pediatritričnih bolnikih.
If you have advanced HIV disease (AIDS) and another infection, you may develop inflammation or worsening of the symptoms of infection when you start treatment with Emtriva. 
Če imate napredovalo bolezen HIV (AIDS) in imate drugo okužbo, se lahko ob začetku zdravljenja z zdravilom Emtriva pri vas razvije vnetje ali poslabšanje simptomov že obstoječe okužbe.
The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8 ± 2.9 µg·h/mL in subjects with normal renal function to 19.9 ± 1.1, 25.0 ± 5.7 and 34.0 ± 2.1 µg·h/mL, in patients with mild, moderate and severe renal impairment, respectively. 
Pri osebah z normalno ledvično funkcijo znaša sistemska izpostavljenost emtricitabinu 11,8 ± 2,9 µg·h/ml (povprečje ± standardni odklon) in naraste do 19,9 ± 1,1, 25,0 ± 5,7 ter do 34,0 ± 2,1 µg·h/ml pri bolnikih z blago, zmerno in resno oslabelostjo.
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbations of hepatitis may lead to hepatic decompensation. 
Pri bolnikih z napredovalo boleznijo jeter ali cirozo, prekinitev zdravljenja ni priporočena, saj eksacerbacije hepatitisa po zdravljenju lahko povzročijo jetrno dekompenzacijo.
Before starting treatment, your doctor may order blood tests to assess kidney function and may advise you to take a reduced dose of the oral solution or prescribe Emtriva hard capsules. 
Pred začetkom zdravljenja bo zdravnik morda naredil krvne preiskave, da bo ocenil delovanje ledvic in vam morda svetoval, da jemljete zmanjšani odmerek peroralne raztopine Emtriva ali predpisal trde kapsule Emtriva.
The apparent total body clearance at steady-state (CL/F) increased with age over the 3-month period with a corresponding decrease in AUC. 
Opažen skupni telesni očistek pri stanju dinamičnega ravnovesja (CL/F) se je v tem trimesečnem obdobju s starostjo večal, vrednost AUC pa se je ustrezno manjšala.
The bottle contains 170 mL of solution. 
Plastenka vsebuje 170 ml raztopine.
Each capsule has a white opaque body with a light blue opaque cap, of dimensions 19.4 mm x 6.9 mm. Each capsule is printed with “200 mg” on the cap and “GILEAD” and [Gilead logo] on the body in black ink. 
Vsaka kapsula ima belo neprosojno telo s svetlo modrim neprosojnim pokrovčkom dimenzije 19,4 mm x 6,9 mm. Na vsaki kapsuli je na pokrovčku odtisnjeno “200 mg” in na telesu “GILEAD” ter [Gilead logo].
No data are available on which to make a dose recommendation in paediatric patients with renal insufficiency. 
Podatki o priporočenem odmerjanju za pediatrične bolnike z ledvično insuficienco niso na voljo.
However, based on the minimal metabolism of emtricitabine and the renal route of elimination it is unlikely that a dose adjustment would be required in patients with hepatic insufficiency (see section 5.2). 
Vendar pa je, ob upoštevanju minimalne presnove emtricitabina in izločanja preko ledvic, malo verjetno, da bi bila pri bolnikih z jetrno insuficienco potrebna prilagoditev odmerka (glejte poglavje 5.2).
If you are unsure how much Emtriva you should take ask your doctor or pharmacist. 
Če ne veste točno, koliko zdravila Emtriva morate vzeti, se posvetujte s svojim zdravnikom ali farmacevtom.
In combination studies of emtricitabine with protease inhibitors (PIs), nucleoside, nucleotide and non-nucleoside analogue inhibitors of HIV reverse transcriptase, additive to synergistic effects were observed. 
V študijah kombinacije emtricitabina z zaviralci proteaz (PI - protease inhibitors), z nukleozidnimi, nukleotidnimi in ne-nukleozidnimi analogi zaviralcev HIV reverzne transkriptaze so opazili aditivne ali celo sinergistične učinke.
Hepatic insufficiency: No data are available on which to make a dose recommendation for patients with hepatic insufficiency. 
Jetrna insuficienca: Podatkov o priporočenem odmerjanju za bolnike z jetrno insuficienco ni na voljo.
Patients with end-stage renal disease (ESRD) managed with other forms of dialysis such as ambulatory peritoneal dialysis have not been studied and no dose recommendations can be made. 
Pri bolnikih z ledvičnim obolenjem v zadnji fazi (ESRD, end-stage renal disease), z drugimi oblikami dialize, kot je npr. ambulantna peritonealna dializa, ni bilo raziskav.
Patients with renal insufficiency can also be managed by administration of Emtriva 10 mg/mL oral solution to provide a reduced daily dose of emtricitabine. 
Bolniki z ledvično insuficienco so lahko zdravljeni tudi z Emtriva 10 mg/ml peroralno raztopino za zagotovitev zmanjšanega dnevnega odmerka emtricitabina.
What Emtriva looks like and contents of the pack 
Izgled zdravila Emtriva in vsebina pakiranja
If the patient vomits more than 1 hour after taking Emtriva they do not need to take another dose. 
Če bolnik bruha več kot 1 uro po jemanju zdravila Emtriva, ne rabi vzeti drugega odmerka.
Please also refer to the Summaries of Product Characteristics of the other antiretroviral medicinal products used in the combination regimen. 
Prosimo, upoštevajte tudi povzetek glavnih značilnosti drugih protiretrovirusnih zdravil kombiniranih pri zdravljenju.
If you accidentally take too many Emtriva hard capsules, contact your doctor or nearest emergency department for advice. 
Če ste pomotoma zaužili preveč trdih kapsul Emtriva, se posvetujte z zdravnikom ali poiščite najbližjo urgentno ambulanto.
How to take Emtriva • Always take this medicine exactly as your doctor has told you. 
Kako jemati zdravilo Emtriva • Pri jemanju tega zdravila natančno upoštevajte navodila zdravnika.
Blood and lymphatic system disorders: Common: 
Bolezni krvi in limfatičnega sistema: Pogosti:
Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. 
Pri bolnikih z jetrnimi boleznimi, vključno s kroničnim hepatitisom B ali C, ki se zdravijo s protiretrovirusnimi zdravili, obstaja povečano tveganje za pojav hudih in potencialno usodnih jetrnih zapletov.
High density polyethylene (HDPE) bottle with a polypropylene child-resistant closure, containing 30 hard capsules. 
Plastenka iz polietilena visoke gostote (HDPE)s polipropilensko za otroke varno zaporko, ki vsebuje 30 trdih kapsul.
The methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) may cause allergic reactions (possibly delayed). 
Metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216) lahko povzročita alergijske reakcije (lahko zapoznele).
• The active substance is emtricitabine. 
• Zdravilna učinkovina je emtricitabin.
In vitro, emtricitabine did not inhibit metabolism mediated by any of the following human CYP450 isoforms: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4. 
In vitro emtricitabin ni inhibiral presnovnih reakcij kateregakoli od naslednjih vpletenih izooblik humanih CYP450: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 in 3A4.
Emtriva oral solution contains: 
Peroralna raztopina Emtriva vsebuje:
Mitochondrial dysfunction following exposure in utero Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. 
Nukleozidni in nukleotidni analogi lahko v različnih stopnjah vplivajo na mitohondrijsko funkcijo, kar je najbolj izrazito pri stavudinu, didanozinu in zidovudinu.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. 
Bolniki s predhodno jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo povečano pogostnost motenj jetrne funkcije v času kombiniranega protiretrovirusnega zdravljenja (CART).
There are no data regarding the efficacy and only very limited data regarding the safety of emtricitabine in infants below 4 months of age. 
Ni podatkov glede učinkovitosti emtricitabina pri dojenčkih, mlajših od 4 mesecev, podatki glede varnosti emtricitabina pa so zelo omejeni.
After opening: Do not store above 25°C. 
Po odprtju: shranjujte pri temperaturi do 25 °C.